Aug 30 (Reuters) - Shares in Instem Plc (INS.L) soared over 39% on Wednesday after the British life sciences software company agreed to a take-private deal with French private equity firm Archimed SAS for 203 million pounds ($256.5 million). Under the terms of the deal with Ichor Management, a company controlled by Archimed, each Instem shareholder will get 833 pence in cash, representing a premium of 41% to the stock's last close. The offer, which Instem's board recommended shareholders accept, caps multiple rejected proposals from Archimed since March. Healthcare-focused investment firm Archimed has more than 8 billion euros of assets under management and investments in 32 healthcare companies. ($1 = 0.7916 pounds)Reporting by Prerna Bedi in Bengaluru; Editing by Sonia Cheema and Eileen SorengOur Standards: The Thomson Reuters Trust Principles.

---

Persons: Archimed, Prerna Bedi, Sonia Cheema, Eileen Soreng Organizations: Instem Plc, SAS, Ichor Management, Archimed, Healthcare, Thomson Locations: London, Archimed, Staffordshire, Bengaluru